It is not clear how Bacillus
Calmette-Guerin (BCG) works to treat
bladder cancer. It may stimulate an immune response or
cause inflammation of the bladder wall that destroys cancer cells within the
bladder. BCG has been used to treat
stage 0 and I cancer but is used most commonly to prevent the return
(recurrence) of noninvasive bladder cancer. It is most often used after cancer
has been removed from the bladder using
transurethral resection (TUR) surgery.
BCG is also used in some countries as a vaccine to provide protection
against
tuberculosis (TB).
BCG is given through a
urinary catheter (intravesically) into the
bladder.
Limit your fluid intake for 4 hours before the
procedure so you will be able to hold the medicine in your bladder during the
treatment. Do not drink caffeinated drinks for 4 to 6 hours before and for 2
hours after the procedure.
Empty your bladder immediately before
the procedure. A
urinalysis is usually done at this
time.
BCG is given through a urinary catheter. You will be asked
not to urinate for 2 hours and to change position every 15 to 20 minutes so the
medicine washes the entire bladder wall.
For 6 hours after
treatment, wash your genital area after every urination to avoid skin
irritation.
Treatment is usually given once a week for 6 weeks. After this,
you may be treated again every 3 to 6 months over the next 2
years.
Burning or pain with urination, a sense of needing to
urinate often, and urinating small amounts often are common effects after BCG
treatment.
BCG is used following TUR surgery for
noninvasive bladder cancer in people who are at medium or high risk for
recurrence of cancer. It can also be used following TUR surgery in people who
cannot have a
cystectomy procedure for bladder cancer, but its
usefulness in these cases is limited.
Research continues to determine the
most effective strain of BCG and the best dosage schedule for the treatment of
bladder cancer. Dosage schedules vary and are determined by your doctor.
If you have major side effects from BCG treatment, you may need more
treatment with
antibiotics and
corticosteroids.
Sylvester RJ, et al. (2004). Intravesical Bacillus
Calmette-Guerin reduces the risk of progression in patients with superficial
bladder cancer: A meta-analysis of the published results of randomized clinical
trials. Journal of Urology, 168 (5):
1964–1970.
Boyd LA (2003). Intravesical Bacillus Calmette-Guerin
for treating bladder cancer. Urologic Nursing, 23(3):
189–199.
This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.